Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

10x Genomics, Inc. (TXG)

NMS · Health Information Services

$47.05+1.13 (+2.46%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$5.97B
P/E (TTM)
EPS
$-0.17
Div Yield
52W Range
$11.16–$49.50
Beta
2.04

Company overview

Next earnings: 2026-08-06(9d)

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Peers in Health Information Services

All in industry →

Recent press releases

10x Genomics, Inc. has not issued a press release in this window.

SEC filings

All filings →

10x Genomics, Inc. has not filed an SEC document in this window.

10x Genomics, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
FMR LLC$194.4M
11,917,482 sh+40.9%
12,667,369 sh+6.6%
13,017,914 sh-1.9%
10,014,462 sh+5.8%
1,242,366 sh-77.2%
4,667,203 sh+33.6%

People at 10x Genomics, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$31.9M
NI -$34.4M
06/25
$8.8M
NI $34.5M
09/25
$149.0M
NI -$27.5M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.22
Prior: $0.28
Revenue sparkline